Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics

Chai, Feng; Hornez, Jean‐Christophe; Blanchemain, Nicolas; Neut, Christel; Descamps, M.; Hildebrand, Hartmut F.

doi:10.1016/j.bioeng.2007.08.001

Cited by 71 publications

(51 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure 4 presents the pores size distribution chart of porous SSS scaffolds. The pores were unimodal and predominantly in the range of 10-70 μm, indicating that they were suitable for drug delivery applications (1), as small pores are known to facilitate high adsorption of drug and to sustain the release better than the larger pores (16). Figure 5 reveals the SEM images of SSS scaffolds subjected to in vitro bioactivity studies at various time points.…”

Section: Characterization Of Porous Scaffoldsmentioning

confidence: 99%

Porous Bioactive Glass Scaffolds for Local Drug Delivery in Osteomyelitis: Development and In Vitro Characterization

et al. 2010

View full text Add to dashboard Cite

Abstract.A new bioactive glass-based scaffold was developed for local delivery of drugs in case of osteomyelitis. Bioactive glass having a new composition was prepared and converted into porous scaffold. The bioactivity of the resulting scaffold was examined by in vitro acellular method. The scaffolds were loaded with two different drugs, an antibacterial or antifungal drug. The effects of the size of the scaffold, drug concentration, and dissolution medium on drug release were studied. The scaffolds were further coated with a degradable natural polymer, chitosan, to further control the drug release. Both the glass and scaffold were bioactive. The scaffolds released both the drugs for 6 weeks, in vitro. The results indicated that the bigger the size and the higher the drug concentration, the better was the release profile. The scaffolds appeared to be suitable for local delivery of the drugs in cases of osteomyelitis.

show abstract

Section: Characterization Of Porous Scaffoldsmentioning

confidence: 99%

Porous Bioactive Glass Scaffolds for Local Drug Delivery in Osteomyelitis: Development and In Vitro Characterization

et al. 2010

View full text Add to dashboard Cite

show abstract

“…, Toshiyuki IKOMA 3) , Shin-ichi KATSUDA 2) , Toru TONEGAWA 4) , Junzo TANAKA 4) , Teppei NAKAMURA 2) , Hidetaka SATO 2) , Shigeo ITO 5) , Nobuya SASAKI 1) and Takashi AGUI ABSTRACT. For chronic kidney disease patients with renal anemia, recombinant human erythropoietin (rHuEPO) is a very effective drug; however, the treatment regime is troublesome, requiring multiple administrations each week. In the present study, we examined the efficiency of hydroxyapatite (HAp) as a drug delivery carrier for the sustained release of erythropoietin (EPO) to reduce the frequency of administration.…”

mentioning

confidence: 99%

“…HAp particles have been examined for application in the sustained release of various therapeutic agents, such as antibiotics [1,11,26,27], anticancer drugs [8,35] and proteins [5,6,18,19]. Nagao et al has reported that HAp has the ability to absorb therapeutic agents without deactivation and shows regulated release as it biodegrades [22].…”

mentioning

confidence: 99%

Sustained Efficacy of Erythropoietin with a Hydroxyapatite Carrier Administered in Mice

Nagasaki

Ikoma

Katsuda

et al. 2009

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. For chronic kidney disease patients with renal anemia, recombinant human erythropoietin (rHuEPO) is a very effective drug; however, the treatment regime is troublesome, requiring multiple administrations each week. In the present study, we examined the efficiency of hydroxyapatite (HAp) as a drug delivery carrier for the sustained release of erythropoietin (EPO) to reduce the frequency of administration. Spray-dried HAp microparticles, formed from zinc-containing HAp (Zn-HAp) and Zn-HAp calcined at 400C, were used as carriers of EPO, and five Zn-HAp formulation samples incorporating EPO were prepared; no formulation, poly-L-lactic acid (PLA) formulation, zinc (Zn) formulation, Zn/PLA formulation, and calcined/Zn/PLA formulation. ICR mice were administered these samples or commercial rHuEPO (Epogin) as a control from dorsal neck subcutaneous, and hematological and histopathological analyses, including enzyme-linked immunosorbent assay for plasma EPO concentration, were performed. An increase in the blood EPO level was detected on days 3 and 8 post-administration. Peak hematopoiesis was delayed and higher hematological values were obtained on day 14 post-administration with no serious adverse reactions compared with the control. The Zn/PLA formulation sample was found to be most effective in reducing the initial peak while sustaining the delayed release of EPO. In conclusion, the Zn-HAp formulation samples were considered to be useful carriers for the sustained release of EPO, and the Zn/PLA formulation appears to be the most effective of five Zn-HAp formulation samples in sustaining EPO release.KEY WORDS: anemia, erythropoietin, hydroxyapatite, sustained release.

show abstract

“…Advantages of this skintargeted approach include the fact that HAp administration is minimally invasive and have neither cellular nor humoral immune response. HAp particles have been examined as a carrier for sustained release of various therapeutic agents, such as antibiotics [2,13,28,29], anticancer drugs [11,33], and proteins [6,8,18,21]. It is known that the protein adsorbed to HAp is difficult to release in vitro, because the protein adsorbed to HAp is released with biodegradation of HAp [24].…”

Section: Resultsmentioning

confidence: 99%

“…, Toshiyuki IKOMA 3) , Shin-ichi KATSUDA 2) , Toru TONEGAWA 4) , Junzo TANAKA 4) , Minami OHYAMA 2) , Kosuke HAYASHIDA 2) , Teppei NAKAMURA 2) , Hidetaka SATO 2) , Shigeo ITO 5) , Nobuya SASAKI 1) and Takashi AGUI 1) Chronic kidney disease (CKD), commonly also known as chronic renal disease, is a progressive and permanent loss of kidney function over a period of months or years. More than 275,000 patients are receiving dialysis treatment in Japan, and that 10 thousands of new patients with CKD increase per year [Japanese Society for Dialysis Therapy, http:// www.jsdt.or.jp/index_e.html].…”

mentioning

confidence: 99%

Amelioration of Anemia in the ICGN Mouse, a Renal Anemia Model, with a Subcutaneous Bolus Injection of Erythropoietin Adsorbed to Hydroxyapatite Matrix

Nagasaki

Ikoma

Katsuda

et al. 2009

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The recombinant human erythropoietin (rhEPO) is used for the treatment of patients with renal anemia. However, rhEPO should be administered subcutaneously or intravenously three times a week. The repetitive injections of rhEPO result in burdens to patients. To resolve this problem, we investigated the sustaining release methods using an rhEPO-hydroxyapatite (HAp) made by spraydrying technique as the drug delivery system. Two types of rhEPO-HAp formulations were prepared; zinc (Zn) formulation and Zn and poly-L-lactic acid (PLA) formulation. These formulations were examined in genetically anemic model, ICGN (ICR-derived glomerulonephritis) mice. According to in vivo release test of rhEPO from HAp in ICGN mice, elevated plasma concentration of rhEPO could be maintained for more than 7 days. These mice showed the amelioration of anemia for more than 3 weeks post-administration without causing any side effect. In conclusion, Zn or Zn/PLA formulation of HAp was considered to be one of the useful carriers of rhEPO for long-term improvement of anemia.KEY WORDS: drug delivery system, erythropoietin, hydroxyapatite, ICGN mice, renal anemia.

show abstract

Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics

Cited by 71 publications

References 14 publications

Porous Bioactive Glass Scaffolds for Local Drug Delivery in Osteomyelitis: Development and In Vitro Characterization

Porous Bioactive Glass Scaffolds for Local Drug Delivery in Osteomyelitis: Development and In Vitro Characterization

Sustained Efficacy of Erythropoietin with a Hydroxyapatite Carrier Administered in Mice

Amelioration of Anemia in the ICGN Mouse, a Renal Anemia Model, with a Subcutaneous Bolus Injection of Erythropoietin Adsorbed to Hydroxyapatite Matrix

Contact Info

Product

Resources

About